Researchers at Cincinnati Children's Hospital Medical Center in collaboration with Roche, have developed a next-generation ...
A new human liver organoid microarray developed by Cincinnati Children’s and Roche recreates immune-driven liver injury in ...
News-Medical.Net on MSN
Microarray platform could help predict immune‐mediated drug‐induced liver injury
Researchers at Cincinnati Children's Hospital Medical Center in collaboration with Roche, have developed a next-generation ...
As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed ...
Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying the hypotheses in humans.
Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T ...
The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.
Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of “non-self” tumor cells. However, in chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback